Every order comes with a free gift!

Management of Tinea Capitis

Brian Holtry
MD, infectious diseases specialist and medical writer

Definition of Tinea Capitis

The term tinea capitis refers to dermatophyte infections of the scalp and hair.

This infection most often affects children and typically presents with patchy hair loss, scaling, or broken hairs. Some patients may have inflammation with pustules or boggy plaques, while others have only subtle flaking, which can delay recognition.

Tinea Capitis

Geographic Distribution of Tinea Capitis

The condition occurs worldwide, but it is most prevalent in Africa, Asia, and southern and eastern Europe, where it is the most common form of dermatophytosis. Improved standards of hygiene and prompt eradication of sporadic infection have led to a marked decline in the incidence of tinea capitis in North America and western Europe. Favus used to be worldwide in distribution, but is now confined to North Africa, the Middle East, and parts of southern and eastern Europe.

Patterns of migration, urban crowding, and close contact among school-aged children also influence local epidemiology, so clinicians in low-incidence countries still encounter imported or clustered cases.

Causal Organisms

Tinea capitis is caused by a number of Trichophyton and Microsporum species. M. canis is a frequent cause of the condition in western Europe, but T. violaceum predominates in eastern and southern Europe and North Africa. T. tonsurans predominates in North America, and is becoming more common in the UK.

Tinea capitis due to anthropophilic Microsporum species is a contagious disease endemic in many countries. It primarily affects children, is more common in males than females, and is most prevalent between 6 and 10 years of age. The disease seldom persists beyond the age of 16. Large outbreaks often occur in schools or other places where children congregate. Zoophilic Microsporum and Trichophyton species are seldom responsible for more than minor outbreaks of human infection. Household pets, such as dogs and cats, are a common source of infection, but feral cats are another prolific source of M. canis.

Tinea capitis due to anthropophilic Trichophyton species is another contagious disease. It is most common in male children under the age of 12.

T. schoenleinii is considered to be the sole aetiologic agent of favus, although infections with other dermatophytes, such as M. gypseum, T. verrucosum and T. violaceum, can sometimes produce somewhat similar lesions. Although T. schoenleinii is an anthropophilic dermatophyte, favus is less contagious than other forms of tinea capitis due to Microsporum or other Trichophyton species. It is usually contracted in childhood and may persist into adult life. Debilitated or malnourished children, or children with a chronic disease such as tuberculosis, are more susceptible to this infection. Instances have been reported in which several generations of the same family were affected.

Together, these organisms account for most cases worldwide, with regional differences reflecting local reservoirs (human, animal, or environmental) and patterns of crowding and hygiene.

Table 1. Tinea capitis organisms and epidemiologic patterns
Region or context Organisms mentioned Typical characteristics
Western Europe M. canis Frequent cause of tinea capitis; often linked to household pets or feral cats.
Eastern and southern Europe, North Africa T. violaceum Predominant anthropophilic species; supports person-to-person spread among children.
North America T. tonsurans Predominant organism; contagious, with cases clustered in schools and families.
United Kingdom T. tonsurans (emerging) Becoming more common, reflecting changing epidemiology and travel patterns.
Favus-endemic areas (North Africa, Middle East, parts of southern and eastern Europe) T. schoenleinii Sole aetiologic agent of favus; anthropophilic dermatophyte, less contagious but may persist into adult life.
Animal-associated infections Zoophilic Microsporum and Trichophyton species, especially M. canis Often related to contact with dogs, cats, or farm animals; usually cause minor human outbreaks.
Host factors - Children 6-10 years old; male predominance; increased risk with malnutrition, chronic disease, or close-contact settings such as schools.

Management of Tinea Capitis

Where possible, specimens for mycological examination should be taken before starting treatment. If oral treatment is being considered, mycological confirmation of the clinical diagnosis is essential before treatment is commenced.

Terbinafine (250 mg/day for 2 weeks) and itraconazole (100 mg/day for 2 weeks) have both proved effective in the oral treatment of tinea capitis, but neither compound is licensed for this indication at present. The duration of griseofulvin treatment depends on the nature of the infection and the clinical response; some infections can take up to 3 months to clear. The usual dosage is 10 mg/kg/day and this should be given after food. Mycological tests should be repeated 1 month after starting treatment and again before discontinuing the drug.

Various topical imidazole preparations can be used to treat localised scalp lesions, including clotrimazole, miconazole, and sulconazole. These drugs are safe and side effects after local application are uncommon.

Systemic therapy is the cornerstone of treatment for most cases of tinea capitis, with topical agents used as adjuncts to reduce surface fungal load and limit transmission. Close follow-up with repeat mycological testing helps confirm cure and guide the duration of therapy.

Table 2. Treatment options for tinea capitis
Therapy Role in management Examples and dosing from text Duration from text
Systemic terbinafine Oral treatment option for tinea capitis* Terbinafine 250 mg/day 2 weeks
Systemic itraconazole Alternative oral treatment option* Itraconazole 100 mg/day 2 weeks
Systemic griseofulvin Established oral therapy; duration depends on clinical response Griseofulvin 10 mg/kg/day, given after food Up to 3 months in some infections
Topical imidazoles Adjunct therapy for localised scalp lesions Clotrimazole, miconazole, sulconazole Used during systemic treatment and until lesions improve
Diagnostic mycology Guides initiation and completion of systemic therapy Mycological tests at baseline, 1 month after starting treatment, and before discontinuation As specified in the text

* The text notes that terbinafine and itraconazole have proved effective but are not licensed for this indication at present.

Tinea Capitis

To prevent epidemics of anthropophilic tinea capitis due to M. audouinii from developing, all contacts of infected children should be examined with Wood's light. Contacts of children with T. tonsurans infection can be screened using the hair brush sampling method. It is seldom practical to exclude infected children from school, in view of the long duration of treatment.

Screening close contacts, examining pets when appropriate, and educating families not to share combs, hats, or hair accessories can help limit spread while treatment is under way.

4 Easy Steps to Get Your Medicines
01
Choose your medicine
02
Fill in Details
03
Pay Online
04
Fast Delivery
Licensed Pharmacy
Certified Medicines Only
Pharmacist Available Online
Discreet Packaging
Fast Delivery
Money-Back Guarantee
Best Price Guarantee
Data Privacy Protected
Medical disclaimer

Content on this website is provided for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or another qualified health provider before starting, changing, or stopping any medication. If you think you may be experiencing a medical emergency, call your local emergency number immediately.

AntiInfectiveMeds does not provide medical diagnosis or prescribe treatment. Use medicines only as directed by your healthcare professional and read the patient information leaflet.

Information about products on this site, including appearance, packaging, and brand names, may vary by manufacturer and country. Availability, regulations, and prescription or import requirements differ from country to country. You are responsible for complying with the laws and prescription requirements in your country.

By using this site, you agree to our Terms and Conditions and Privacy Policy.